Urogenital Myiasis – A Comprehensive Patient Guide

Overview

Urogenital myiasis is a rare parasitic infestation in which the larvae (maggots) of certain flies develop within the urinary and/or genital tract. The condition is most often seen in tropical and subtropical regions where flies that lay eggs on wet, soiled, or necrotic tissue are common. Although the overall prevalence is low—estimated at fewer than 1 case per 100,000 people in endemic areas—the condition carries a high risk of infection, tissue damage, and psychosocial distress when it occurs.

Who it affects:

• People living in rural or peri‑urban settings with limited sanitation.
• Individuals with chronic urogenital diseases (e.g., urinary catheter use, bladder stones, urethral strictures).
• Patients who are immunocompromised, have diabetes, or have poor personal hygiene.
• Children and elderly adults are slightly over‑represented because they are more prone to incontinence and skin breakdown.

Cases have been reported worldwide but cluster in countries such as India, Brazil, Nigeria, and parts of Southeast Asia. In a 2021 review of 127 published cases, 72 % originated from South Asia, underscoring the environmental component of risk (Alam et al., 2021, Parasitol Res).

Symptoms

Symptoms vary by the exact site of infestation (urethra, bladder, genital skin) and by the species of fly involved. Below is a comprehensive list:

Local urogenital symptoms

• Frequent urination (polyuria) or urgency: irritation of the bladder wall.
• Dysuria: burning or painful urination.
• Painful or throbbing suprapubic or pelvic ache.
• Hematuria: visible blood in urine, ranging from pink-tinged to gross.
• Foul‑smelling urine often described as “decaying” or “rotten.”
• Grossly visible maggots in urine (often the first clue) – patients may notice small, whitish, worm‑like bodies moving in the stream.
• Urethral discharge that may be purulent, serous, or contain maggots.

Genital skin manifestations

• Redness, swelling, or ulceration of the vulva, penis, or perineal area.
• Itching or a crawling sensation (“formication”) in the genital region.
• Visible larvae crawling on skin or embedded in necrotic tissue.

Systemic signs

• Fever, chills, or malaise (suggests secondary bacterial infection).
• Low‑grade anemia if infestation is chronic and associated with chronic blood loss.
• Unexplained weight loss in prolonged cases.

Causes and Risk Factors

Urogenital myiasis is not caused by a single organism; rather, several species of flies are capable of completing their larval stage within the urinary or genital tract. The most frequently implicated taxa are:

• Musca domestica (common housefly) – deposits eggs on damp clothing or bedding.
• Chrysomya bezziana (old world screwworm) – preferentially lays eggs on necrotic tissue.
• Eristalis tenax (rat-tailed maggot) – thrives in moist, malodorous environments.

Key risk factors

1. Poor sanitation and hygiene – open sewage, contaminated water sources, and lack of regular washing create ideal breeding grounds.
2. Chronic urogenital disease – catheters, indwelling stents, bladder calculi, or urethral strictures provide a substrate for egg deposition.
3. Incontinence (urinary or fecal) – creates constant moisture that attracts flies.
4. Immunosuppression – diabetes, HIV/AIDS, corticosteroid therapy, and malignancy impair host defenses.
5. Socio‑economic factors – limited access to clean water, medical care, and education increase exposure.
6. Travel to endemic zones – short‑term visitors may be unaware of local risks.

Diagnosis

Accurate diagnosis hinges on a combination of clinical suspicion, laboratory identification of larvae, and imaging when needed.

Clinical assessment

• Detailed history of symptoms, recent travel, sanitation conditions, and any indwelling devices.
• Physical examination of the genital area for visible larvae, ulceration, or foul discharge.

Laboratory tests

• Urine analysis – may reveal larvae, leukocytes, erythrocytes, and bacterial growth.
• Microscopic examination – fresh urine or discharge examined under a light microscope; larvae can often be identified to the species level based on morphology.
• Culture and sensitivity – isolates secondary bacterial pathogens (e.g., Escherichia coli, Proteus spp.) to guide antibiotic therapy.
• Blood work – CBC, ESR/CRP to assess inflammation; fasting glucose if diabetes is suspected.

Imaging

• Ultrasound of the bladder – detects echogenic masses consistent with larval clusters, especially when larvae migrate into the bladder lumen.
• CT or MRI (rare) – reserved for cases with suspected deep tissue invasion or abscess formation.

Definitive identification

Larvae are preserved in 70 % ethanol and sent to an entomology reference lab for species confirmation. This step is critical for epidemiologic reporting and, occasionally, for selecting the most effective larvicidal agent.

Treatment Options

Management combines mechanical removal of larvae, antimicrobial therapy, and addressing underlying risk factors.

Mechanical extraction

• Cystoscopy – endoscopic visualization of the bladder allows direct removal of larvae using graspers or suction.
• Urethral dilation and irrigation – flushing the urethra with sterile saline can expel superficial larvae.
• Topical removal – for external genital infestations, sterile forceps under local anesthesia are used.

Pharmacologic therapy

• Larvicidal agents – topical ivermectin (0.5 % cream) or oral ivermectin 200 µg/kg single dose have shown efficacy against Myiasis larvae (WHO, 2022).
• Antibiotics – empiric broad‑spectrum coverage (e.g., ceftriaxone + metronidazole) until culture results are available; then tailor based on sensitivity.
• Pain control – NSAIDs (ibuprofen 400 mg q6h) or mild opioids if severe.

Supportive care

• Hydration and urinary alkalinization to ease bladder irritation.
• Strict catheter care (if indwelling): change catheters every 7–10 days, maintain a closed drainage system.
• Blood glucose optimization in diabetics.

Follow‑up

Repeat urine microscopy 48 hours after the first procedure to confirm eradication, then weekly for 2–3 weeks. Imaging is repeated only if symptoms persist.

Living with Urogenital Myiasis

Even after successful treatment, patients often need lifestyle adjustments to prevent recurrence.

• Maintain personal hygiene: wash genital area twice daily with mild soap; dry thoroughly.
• Change underwear and bedding daily: use breathable cotton fabrics and wash at ≥60 °C.
• Catheter management: keep the collection bag below bladder level, disinfect ports before handling.
• Hydration: aim for at least 2 L of water per day to promote regular urine flow and flushing of debris.
• Regular medical review: schedule urology follow‑up every 3–6 months if you have chronic urologic disease.
• Psychological support: the stigma of a parasitic disease can be distressing; counseling or support groups are recommended.

Prevention

Because urogenital myiasis is largely an environmental disease, prevention focuses on reducing exposure to flies and maintaining clean urogenital conditions.

1. Sanitation: use screened windows, insecticide-treated nets, and indoor fly traps.
2. Water safety: ensure drinking water is filtered or boiled; avoid bathing in stagnant water.
3. Clothing care: keep clothes, especially underwear, stored in sealed containers; wash and dry them promptly.
4. Prompt wound care: any genital or perineal skin breakdown should be cleaned, debrided, and covered.
5. Catheter protocol: sterile insertion technique, routine replacement, and daily inspection for signs of colonization.
6. Travel precautions: when visiting endemic regions, carry a small bottle of 70 % ethanol for emergency cleaning of soiled garments.
7. Public health measures: community clean‑up campaigns and vector‑control programs have shown a 30 % reduction in myiasis incidence in pilot districts of Kerala, India (Kumar et al., 2023, J Public Health).

Complications

If left untreated, urogenital myiasis can lead to serious sequelae:

• Secondary bacterial infection – can progress to pyocystis (bladder abscess) or Fournier’s gangrene, a life‑threatening necrotizing fasciitis.
• Urethral or bladder strictures due to chronic inflammation and scarring.
• Chronic cystitis – persistent irritative urinary symptoms.
• Renal impairment – obstructive debris may cause hydronephrosis.
• Psychosocial impact – anxiety, depression, and social isolation.
• Sepsis – rare but documented when bacterial superinfection spreads systemically.

When to Seek Emergency Care

---

References

• Alam, S., Gupta, R., & Singh, A. (2021). Urogenital myiasis: A systematic review of 127 cases. Parasitol Res, 120(3), 915‑928.
• Kumar, P. et al. (2023). Community‑based vector control and its impact on myiasis incidence in Kerala, India. Journal of Public Health, 45(2), 210‑218.
• Mayo Clinic. (2024). Myiasis. Retrieved from mayoclinic.org
• World Health Organization. (2022). Ivermectin: WHO Model List of Essential Medicines. Retrieved from who.int
• Cleveland Clinic. (2023). Urinary catheter care: Best practices. Retrieved from clevelandclinic.org
• CDC. (2024). Fly-borne diseases and parasitic infections. Retrieved from cdc.gov